THE 20-CORE PROSTATE BIOPSY SCHEME CAN REDUCE THE GLEASON SUM UPGRADING IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER

You have accessJournal of UrologyProstate Cancer: Detection and Screening1 Apr 2011845 THE 20-CORE PROSTATE BIOPSY SCHEME CAN REDUCE THE GLEASON SUM UPGRADING IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER Amine Benchikh El Fegoun, Pourya Pashootan, Vincent Hupertan, Antoine Wallois, Laurence Choudat, Sebastien Dominique, Jean-François Hermieu, and Vincent Ravery Amine Benchikh El FegounAmine Benchikh El Fegoun Paris, France More articles by this author , Pourya PashootanPourya Pashootan Paris, France More articles by this author , Vincent HupertanVincent Hupertan Paris, France More articles by this author , Antoine WalloisAntoine Wallois Paris, France More articles by this author , Laurence ChoudatLaurence Choudat Paris, France More articles by this author , Sebastien DominiqueSebastien Dominique Paris, France More articles by this author , Jean-François HermieuJean-François Hermieu Paris, France More articles by this author , and Vincent RaveryVincent Ravery Paris, France More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.666AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To compare the accuracy and efficacy of a standard (10–12 cores) versus an extended (20 cores) biopsy protocol, in predicting the Gleason score at final radical prostatectomy (RP) pathology in patients with low- and intermediate-risk prostate cancers. METHODS We retrospectively evaluated 339 patients who underwent a RP at our institution between 2000 and 2007. Between 2000 and 2005 all patients underwent a 10-core biopsy protocol (group A), whereas between 2005 and 2007 they all underwent a 20-core biopsy protocol (group B). Gleason sum upgrading (GSU) was defined as a change from 6 or 7 (3+4) at biopsy to 7 (4+3) or more at final RP pathology. RESULTS The overall mean age was 63.5 years, with a median prostate-specific antigen (PSA) level of 6.9 ng/mL. Mean age, initial PSA, prostate volume and clinical stage, were comparable in both groups. In the whole group of 339 patients, the GSU was 26.2% whereas the Gleason score remained the same in 73.8%. In group A, the GSU was 28.1% compared to 18.7% in group B (P < .05). CONCLUSIONS In patients with low- or intermediate-risk prostate cancers, a 20-core biopsy protocol can attenuate the risk of GSU. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e340 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Amine Benchikh El Fegoun Paris, France More articles by this author Pourya Pashootan Paris, France More articles by this author Vincent Hupertan Paris, France More articles by this author Antoine Wallois Paris, France More articles by this author Laurence Choudat Paris, France More articles by this author Sebastien Dominique Paris, France More articles by this author Jean-François Hermieu Paris, France More articles by this author Vincent Ravery Paris, France More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...